General form of registration statement for all companies including face-amount certificate companies

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
OPERATING ACTIVITIES        
Net (loss) income $ (4,651,858) $ 7,922,013 $ (1,311,951) $ (2,300,196)
Adjustments to reconcile net (loss) income to net cash used in operating activities:        
Depreciation and amortization 504,543 444,658 933,600 767,254
Amortization of debt discount 15,669 589,474 589,474 210,526
Stock issued pursuant to employment agreement 0 35,075 42,125 5,650
Stock-based compensation 2,344,286 0 7,915,833 0
Stock issued for services 366,000 0    
Loss on equity investment 0 38,552 38,552 310,754
Gain on sale of equity investment 0 (7,899,306) (7,899,306) 0
Interest accrued on notes receivable (60,822) 0    
Bad debt expense     (300,000) 400,000
Other     34,816 0
Change in operating assets and liabilities:        
Prepaid expenses and other current assets (6,767) 38,215 (352,787) (174,317)
Prepaid inventory (3,225,506) (1,019,029) 1,215,211 (474,321)
Inventory 1,767,145 (1,399,166) (9,192,929) (2,127,845)
Accounts receivable (857,323) (513,051) 1,205,952 (1,744,064)
Accounts payable and accrued expenses (21,614) 729,507 190,859 24,622
Accrued expenses     178,552 222,703
Net cash used in operating activities (3,826,247) (1,033,058) (6,711,999) (4,879,234)
INVESTING ACTIVITIES        
Cash received on acquisition     0 50,775
Purchase of equipment (89,983) (213,859) (449,211) (226,594)
Cash paid on PhytoSPHERE agreement     0 (950,000)
Investment in KanaLife Sciences     0 (750,000)
Issuance of note receivable     (1,200,000) 0
Repayment of principal on notes receivable 151,522 118,658 264,827 0
Net cash provided by (used in) investing activities 61,539 (95,201) (1,384,384) (1,875,819)
FINANCING ACTIVITIES        
Common stock issued for cash 2,520,000 8,247,500 8,247,500 2,731,423
Proceeds from convertible debt 1,020,000 0    
Convertible debt issuance costs (266,024) 0    
Proceeds from (payment of) loan from Roen Ventures 0 (92,069)    
Proceeds from loan from Roen Ventures, LLC     0 6,192,069
Repayment of loan to Roen Ventures, LLC     (92,069) (100,000)
Repayment of related party loan 0 (300) (300) (200)
Common stock to be issued     0 175,000
Net cash provided by financing activities 3,273,976 8,155,131 8,155,131 8,998,292
Net (decrease) increase in cash (490,732) 7,026,872 58,748 2,243,239
Cash, beginning of period 2,302,418 2,243,670 2,243,670 431
Cash, end of period 1,811,686 9,270,542 2,302,418 2,243,670
Supplemental disclosure of non-cash transactions:        
Value of debt discount     0 800,000
Accounts receivable assumed from acquisition     0 396,438
Inventory assumed from acquisition     0 345,477
Prepaid inventory assumed from acquisition     0 1,260,510
Property and equipment assumed from acquisition     0 1,288
Goodwill     0 1,855,512
Intangible assets acquired from acquisition     0 4,110,000
Amount due to PhytoSPHERE Agreement     0 (1,314,878)
Common Shares issued for acquisition     0 7,070,000
Conversion of accounts receivable to notes receivable 0 6,000,000 (600,000) 0
Conversion of line of credit to common stock 0 (600,000) 6,000,000 0
Common stock to be issued 0 (175,000) (175,000) 0
Common stock received in exchange for sale of investment 0 8,300,000 8,300,000 0
Supplemental cash flow disclosures:        
Interest paid 1,289 187,453 187,453 0
Taxes paid $ 24,854 $ 44,766 $ 0 $ 0